Bioxytran (BIXT) Total Debt (2010 - 2026)
Bioxytran (BIXT) posted Total Debt of $355598.0 for Q1 2026, down 10.13% sequentially from $395668.0 in Q4 2025, and up 640.83% YoY from $48000.0 in Q1 2025.
Bioxytran (BIXT) Total Debt (2010 - 2026) Analysis & Trends
Bioxytran has reported Total Debt for 16 years, with the latest figure at $355598.0 in Q1 2026.
- Quarterly Total Debt rose 640.83% year-over-year to $355598.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $355598.0 (up 640.83% YoY) and the FY2025 annual result came in at $395668.0, up 64.12% from the prior year.
- Total Debt slipped to $355598.0 in Q1 2026 per BIXT's latest filing, from $395668.0 in the prior quarter.
- Over five years, Total Debt peaked at $3.8 million in Q2 2022 and troughed at $38000.0 in Q3 2024.
- A 5-year average of $1.2 million and a median of $781291.5 in 2024 frame the typical range for Total Debt.
- The sharpest annual moves came in 2024 and 2025: Total Debt sank 98.03% in 2024, then jumped 1324.75% in 2025.
- Over 5 years, Total Debt stood at $2.3 million in 2022, then retreated by 6.56% to $2.1 million in 2023, then tumbled by 88.78% to $241078.0 in 2024, then soared by 64.12% to $395668.0 in 2025, then declined by 10.13% to $355598.0 in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $355598.0, $395668.0, and $541405.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 9.34 Bn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 355,598.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355,598.00 |
| Dec 31, 2025 | 395,668.00 |
| Sep 30, 2025 | 541,405.00 |
| Jun 30, 2025 | 48,070.00 |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | 241,078.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 70,974.00 |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Sep 30, 2022 | 2.17 Mn |
| Jun 30, 2022 | 3.77 Mn |
| Dec 31, 2021 | 2.25 Mn |
| Mar 31, 2021 | 420,750.00 |
| Sep 30, 2020 | 8,115.00 |
| Jun 30, 2018 | 25,000.00 |